Thursday, June 5, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

FDA Okays Pluvicto for Earlier Use in Prostate Cancer

March 31, 2025
in Health News
Share on FacebookShare on Twitter


The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), who have received androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.

The radioligand therapeutic agent was previously approved for the treatment of PSMA-positive mCRPC in patients who have already received ARPI therapy and taxane-based chemotherapy. Approval for the expanded indication was based on efficacy demonstrated in the randomized, open-label, phase 3 PSMAfore trial.

Treatment in 468 patients who progressed on one ARPI and who were deemed appropriate for delay of taxane-based chemotherapy was associated with improved radiographic progression-free survival (rPFS) and overall survival (OS) vs a different ARPI.

Patients were randomized 1:1 to receive lutetium Lu 177 vipivotide tetraxetan (7.4 GBq [200 mCi] every 6 weeks for six doses) or to receive a different ARPI, according to a statement from the FDA. Those who progressed on the new ARPI were allowed to cross over to the experimental therapy arm after progression, and 60% did so.

Median rPFS was 9.3 vs 5.6 months in the experimental and control arms, respectively (hazard ratio [HR], 0.41). Median OS durations were 24.5 and 23.1 months, respectively (HR, 0.91), but the difference in OS did not reach statistical significance.

Adverse reactions were consistent with the known safety profile of lutetium Lu 177 vipivotide tetraxetan, which includes possible radiation exposure, myelosuppression, and renal toxicity.

The recommended dose, according to prescribing information, is 7.4 GBq (200 mCi) administered intravenously every 6 weeks for six doses or until disease progression or unacceptable toxicity.

“The earlier indication for Pluvicto could really change our treatment paradigms for patients with mCRPC. It offers a targeted therapy that better delays disease progression compared to a second ARPI,” Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, New York, and the principal investigator of the study in the United States stated in a Novartis press release. “This approval is a significant step forward and should open the doorway to a therapy that has clear clinical advantages for the patient with mCRPC who has progressed on one ARPI and has not received chemotherapy.”

Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape Medical News, MDedge, and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at [email protected] or on X @SW_MedReporter.





Source link : https://www.medscape.com/viewarticle/fda-approves-pluvicto-earlier-use-psma-positive-metastatic-2025a10007ln?src=rss

Author :

Publish date : 2025-03-31 08:47:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Why Some Ob/Gyns Are Walking Away

Next Post

Safety of Systemic Psoriasis Rxs Studied in Older Adults

Related Posts

Health News

Biomarker sNfL Falls Short for MS Diagnosis, Experts Say

June 5, 2025
Health News

Patients With HS, Obesity Report Improvements With GLP-1 RAs

June 5, 2025
Health News

Greater awareness not more cases behind ADHD surge, study suggests

June 5, 2025
Health News

First bacteria we meet can keep us out of hospital

June 5, 2025
Health News

Pregnant women warned against using weight-loss jabs

June 5, 2025
Health News

Is ADHD on the rise? No – but that answer doesn’t tell the whole story

June 5, 2025
Load More

Biomarker sNfL Falls Short for MS Diagnosis, Experts Say

June 5, 2025

Patients With HS, Obesity Report Improvements With GLP-1 RAs

June 5, 2025

Greater awareness not more cases behind ADHD surge, study suggests

June 5, 2025

First bacteria we meet can keep us out of hospital

June 5, 2025

Pregnant women warned against using weight-loss jabs

June 5, 2025

Is ADHD on the rise? No – but that answer doesn’t tell the whole story

June 5, 2025

SGLT2 Inhibitor Shows Promise as MASH Treatment

June 4, 2025

HELP Committee Supports Reauthorizing FDA Program to Streamline Review of OTC Drugs

June 4, 2025
Load More

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version